Introduction
In 1975, genetic screening had been defined as the search in a population for persons possessing certain genotypes that (1) are already associated with disease or predispose to disease, (2) may lead to disease in their descendants, or (3) produce other variations not known to be associated with disease. 1 Today, genetic screening may be defined as any kind of test performed for the systematic early detection or exclusion of a hereditary disease, the predisposition to such a disease or to determine whether a person carries a predisposition that may produce a hereditary disease in offspring. With better knowledge of the genetics of various diseases and a larger capacity of genetic technology, genetic screening at an early stage for an increasing number of medical disorders is possible. Justifications offered in support of genetic screening include early diagnosis and treatment and reproductive decisions. Genetic screening refers to explicit and systematic programmes directed either at whole populations of asymptomatic individuals or at subpopulations in which risk is known to be increased. Genetic screening has to be distinguished from genetic testing because the implications are different. Genetic testing is carried out on patients who for whatever reason have taken the initiative and seek professional advice. In genetic screening, tests may be seen to be imposed on individuals. The ethical dilemmas are magnified and the responsibilities for the physician correspondingly greater. 2 The genetic nature of a disorder results in risk implications to family members of the person screened, even though they may not be, nor perhaps wish to be, included in the screening programme. Genetic screening is also distinguished from other forms of screening because it does not necessarily lead to the prevention or treatment of diseases.
The possible detrimental effects of genetic screening include fear of undue pressure on individual choice, or social stigmatization of persons who might say no to an offer of genetic screening. Consequently, the threat of misuse of genetic screening requires safeguards. Criteria for introducing genetic screening programmes should include ethical considerations as well as public health ones. Genetic screening goals and the target population must be well defined; laboratory quality control stringent, with limits of results clearly delineated; the confidentiality of the information protected by authorities; procedures to protect individual and family privacy established in advance; participation voluntary; genetic counselling offered and educational programs in place; and long-term outcomes monitored and evaluated. The availability of genetic tests at low cost in some countries already seems to be leading to the systematic offer of screening tests without the appropriate medical environment for providing information prior to testing as well as comprehensively explaining the results afterwards. The risk is perhaps low in most European countries where access to health care is organized as public service, but there remains the problem of controlling the importation of tests that could be sold outside of the health system. There is, therefore, a need to introduce effective and acceptable safeguards, standards and procedures relating to informed consent, counselling and confidentiality, and to the risk of discrimination in employment and insurance.
This document does not discuss genetic screening programmes already well-implemented, but focuses on the issues surrounding potential screening programmes that require further discussion before their introduction.
This document aims to increase, among the health-care professions and health policy-makers, awareness of the potential screening programmes as an issue of increasing concern to public health.
Methods
The methods used for analyzing the principles, the techniques, the practices, and the policies of genetic screening were primarily the review of the existing professional guidelines, regulatory frameworks and other documents related to population genetic screening programmes in Europe. Then, with the help of the existing guidelines and a review of literature, the method was to examine questions that need debate, with respect to different types of genetic screening before and after birth. Screening for conditions such as cystic fibrosis (CF), Duchenne muscular dystrophy (DMD), familial hypercholesterolemia, fragile X syndrome, hemochromatosis, and cancer susceptibility was discussed. Special issues related to genetic screening were also examined, such as informed consent, family aspects, commercialization, the players on the scene and monitoring genetic screening programmes. Afterwards, these questions were debated during an international workshop organized by the European Society of Human Genetics Public and Professional Policy Committee in Amsterdam, the Netherlands, November, 19 -20, 1999 .
The purpose of the workshop was to identify, from a professional viewpoint, the most important/pressing/burning ethical issues relating to population genetic screening programmes in Europe. The issues were discussed throughout the following four sessions: (1) general aspects of genetic screening; (2) programmes before birth; (3) programmes after birth; and (4) ethical issues raised by such programmes.
A group of 51 experts from 15 European countries was invited. These experts were representatives of the seven following sectors:
1. Medical genetics 2. Human genetics societies 3. Ethical, legal and social issues 4. Support groups 5. Biotechnology/pharmaceutics 6. Insurance/employment 7. European union institutions A first background document was used for the discussions during the workshop. A second document, including discussions of the workshop, was sent for comments to representatives of the human genetic societies and European experts in the field of population genetic screening programmes, as well as to all ESHG members. This document was also put on the ESHG website (www.eshg.org) for public consultation and discussion. The final document was approved by the ESHG board.
Recommendations were developed by the ESHG-PPPC and they were endorsed at the Amsterdam ESHG annual meeting in May 2000 by the ESHG members; they have been also endorsed by the Board of Directors of the American Society of Human Genetics. The recommendations have been published in the Europ J Hum Genet (vol. 8, no. 9, September 2000).
Review of literature
General principles for genetic screening Both at the national and supranational levels, guidelines have been elaborated with a view to the developments in genetic screening and the ethical issues raised by it. All these documents deal with the question as to which requirements apply to screening programmes. In any genetic screening programme, guidelines should be established governing its aim, limitations, scope, and ethical aspects, as well as the storage and registration of data or material, the need for follow-up (including social consequences), and the risk of side effects. The two most frequently cited objectives of genetic screening are to reduce the prevalence of the disorder and to inform individuals and couples at risk about their reproductive choices. Particular attention is being paid to the rights of participants in terms of informed consent, confidentiality, and data protection.
WHO Guidelines for screening for disease In 1968, the World Health Organization enumerated the following 10 guidelines that should be considered prior to the implementation of a screening programme:
Is the disease an important health problem? Is there a recognizable latent or early symptomatic stage? Do we know the natural history of disease? Is there an effective treatment for patients with recognized disease? Is there a suitable test that will identify the disease in its early stages? Is the test acceptable to the population? Do we agree on who treats the disease? Are facilities for diagnosis and treatment available? Case finding should be ongoing. The cost of case finding (including diagnosis and treatment) should be economically balanced in relation to possible expenditures on medical care as a whole.
The authors stated a fundamental presumption, namely, the requirement that the course of the disease must be modifiable or preventable by early detection and treatment or intervention. 3 A great concern was the most appropriate time to screen to effect the best outcome for the individual along with a concomitant sensitivity towards issues involving communication, consent and labelling. The extend to which a disease was an important health problem varied according to the number of cases of the disorder and its severity. The authors considered that the implications of disease burden should be viewed both from the population health perspective and that of the individual. What constituted a sufficiently large burden to justify screening would depend on the cost of screening and follow-up.
The 1968 WHO guidelines were given before prenatal diagnosis and carrier testing was possible. Therefore, they apply only to a subset of screening today. 4 In 1998, the WHO has reiterated that the main objective of genetic screening is to prevent disease or secure early diagnosis and treatment. They have reaffirmed the voluntary use of genetic screening and proposed the following guidelines:
Genetic screening should be voluntary, not mandatory; Genetic screening should be preceded by adequate information about the purpose and possible outcomes of the screen or test and potential choices to be made; Anonymous screening for epidemiological purposes may be conducted after notification of the population to be screened; Results should not be disclosed to employers, insurers, schools, or others without the individual's consent, in order to avoid possible discrimination;
In rare cases where disclosure may be in the best interests of the individual or of public safety, the health provider may work with the individual towards a decision by him/her; Test results should be followed by genetic counselling, particularly when they are unfavorable; If treatment or prevention exists or is available, this should be offered with a minimum of delay; Newborn screening should be mandatory and free of charge if early diagnosis and treatment will benefit the newborn.
Council of Europe recommendations The Council of
Europe has also adopted recommendations on genetic screening between 1990 and 1994. In these recommendations, genetic screening is defined as 'a test applied to a defined group of persons in order to identify an early stage, a preliminary stage, a risk factor or a combination of risk factors of a disease'. The aim of screening is 'to cure the disease or prevent or delay its progression or onset by early intervention'. The Council points out that 'because there are differences in health needs and health services, as well as in ethical values and in legal norms and rules between countries, the decision to implement a screening programme should be taken in cooperation with the medical profession by each country'. In 1997, the Convention for the Protection of Human Rights and Dignity of the Human
Being with Regard to the Application of Biology and Medicine has endorsed these recommendations. The Committee of Ministers of the Council of Europe thinks that the public generally recognizes the benefits and the potential usefulness of genetic screening for individuals, for families, and for the population as a whole, but it says that there is an accompanying anxiety that genetic screening arouses. Its recommendations to allay any future unease include: informing the public in advance; educating professionals to provide quality services; offering appropriate, nondirective, counselling; providing equality of access; respecting the self-determination of those tested; making screening noncompulsory; and denying insurers the right to require testing or to seek the results of previous tests. In the area of data protection and professional secrecy, genetic information for diagnosis or prevention of disease and for research should be stored separately from other personal records. In addition, those handling the information should be bound by professional rules of confidentiality and legislative rules, and any unexpected findings should be given only to the person tested.
The Nuffield Council on Bioethics, genetic screening: ethical issues The improvement of the health of persons who suffer from genetic disorders should be the first aim of genetic screening: 'the benefits of screening should be seen as enabling individuals to take account of the information for their own lives and empowering prospective parents to make informed choices about having children'. The report drew on experience of screening for serious diseases such as CF and sickle cell anemia while recognizing that it is difficult to define which disease can be considered serious. The report examines other issues such as voluntariness, informed consent, counselling, confidentiality, and the possible use of genetic information by insurers or employers. The Nuffield Council on Bioethics considers that genetic research differs from many medical advances because of the speed of its development, its effect on individuals, families and the general society, and also the 'fear it arouses that it may be interfering with the basis of life itself'. In other respects, current genetic screening programmes should not result in any stigmatisation or compulsion. The Council feels that family members have a legitimate and strong interest in knowing the results of the person tested; when disclosure of screening results to other family members is vital, the Nuffield Council suggests persuasion as a strategy to minimize potential harmful consequences to family members. 5 The report called for the establishment of a central coordinating body to monitor genetic screening programmes once they are in place to make sure that they are: (1) following proper standards and criteria in providing information to people; (2) not introducing an element of compulsion; (3) protecting the data; (4) following any guidelines and rules that have developed in relation to the release of data for insurance. The coordinating body should also assess and recommend to government the value of establishing a screening programme before its inception. The conclusions of the report have been widely endorsed.
The Danish Council of ethics and mapping of the human genome The Danish Council of Ethics defines genetic screening as 'the study of the occurrence of a specific gene or chromosome complement in a population or population group'. The motives for introducing screening programmes are that an individual has a right to expect community-based help like 'offering information that enhances choice and scope for action'. The duty to help is interpreted in terms of autonomy and self-determination, rather than promoting the health of the individual or the genetic health of the population. Counselling must be available and nondirective.
The Danish Council of Ethics views genetic information as different from other private information since it reveals knowledge not only about an individual, but also the individual's relatives, and because analyses will provide comprehensive information about both individuals and population groups. The Council says that screening provides information useful either to the individual or to public health officials, but this information is not concerned with treatment. From a public health point of view, testing may prevent costly treatment of a disease, protect third parties, and give the person the option of treatment. However, from the individual's point of view, there may be ambivalence about the possibility of a relative's potential disease.
The report draws attention to the danger of stigmatization in cases where some minority ethnic groups have a higher frequency of a particular gene. The report recognizes the possibility that termination on the grounds of genetic disorder might lead to decreased acceptance of such disorders in the population. But the Danish Council does not specify the role of public authorities concerning genetic screening within the health-care system.
The Health Council of the Netherlands: Committee Genetic Screening, Genetic Screening The Dutch Health Council defines genetic screening as 'any kind of test performed for the systematic early detection or exclusion of a hereditary disease, the predisposition to such a disease or to determine whether a person carries a predisposition that may produce a hereditary disease in offspring'. The Council states that 'the programme for the early detection and treatment of diseases should involve an important health problem'. However, according to the Council, 'it is up to the individual and parents to determine whether a condition is serious enough to enter a screening programme'; genetic screening aims 'to enable people to achieve greater autonomy and to decide upon a course of action that is acceptable to them'. In other respects, 'a genetic test offered to all may advance equal access to health services, but an offer to a group with an increased risk can be justified'.
The Dutch report remarks that 'an invitation to undergo screening will confront people with risks of which they are not fully aware and this may cause anxiety'; possible stigmatization of participants may also influence compliance. Because of that, 'voluntary participation based on well-understood information is an absolute requirement and there must be safeguards for free individual choice during the whole screening process'. Counselling is also considered important.
Regarding disclosure of screening results to others, the Dutch Council refers to the 1989 report 'Heredity: science and society' for its stance on disclosure of information to others: 'consent of the person tested is needed for disclosure to relatives. If this consent is refused and if the screenee cannot be motivated to give consent, the counsellor or physician is not allowed to disclose the information'.
An authorization must be obtained for screening for serious diseases and abnormalities that cannot be treated or prevented. This authorization will be rejected if the anticipated benefits are outweighed by the attendant risks to the health of the persons examined.
Genetic screening programmes
Although basic requirements for a genetic screening programme are prominent in the literature, there is little consensus on which disorders merit screening, which screening test should be used in practice, which elements should be included to estimate the costs or benefits of screening, and how these should be measured, the appropriate level of resourcing, or how to resolve conflicts that arise between individual and collective interests. 6 Other factors seem also affect the use of genetic screening, such as customs of care, education of the public about the results and limitations of genetic testing, or stigmatization and discrimination issues.
Types of genetic screening There are different types of genetic screening: (1) Genetic screening before birth: which includes screening on fetal cells in maternal blood, maternal serum screening, ultrasound screening, screening on fetal cells obtained after amniocentesis or CVS, and preimplantation genetic diagnosis. The major reason for genetic screening before birth is to detect genetic disorders during early pregnancy. Information can be provided to enable couples to consider to terminate or to continue the pregnancy, while the early diagnosis would allow appropriate plans to be made for treatment and follow-up. 7 (2) Genetic screening after birth: which includes neonatal screening, carrier screening at antenatal clinics, preconceptional carrier screening, cascade screening, school-age screening, and adults screening. Genetic screening after birth has two purposes. First, it can confirm that the person tested either has, or does not have, certain genetic characteristics, with implications for own future health. The second reason for an adult to be tested is to see if their children will be at risk.
Whatever type of genetic screening, the importance of educating individuals about their options is very important. Adequate understanding of the disease and reproductive options are critical to informed decision-making. Because of the combination of benefit and harm in all procedures, the individuals being screened must receive full and accurate information about the procedure and give their informed consent. It has been argued that when uncertainty exists, it should be discussed and advice should be explicitly supported by the best available evidence. 8 In UK, the General Medical council's guidance on seeking patients' consent makes it clear that physicians must make sure that patients are provided with all the information they want or ought to have to make a properly informed decision. 9 Since there is uncertainty about how much information needs to be given before screening, quality of information and access to full information for those who wish it is very important.
Before birth Genetic screening has largely been introduced into prenatal care. 10 Prenatal screening focus on the early detection of serious disorders. Prenatal screening attempts to identify fetuses at an increased risk of anomalies based on family history or increased maternal age or screening tests such as maternal serum testing and ultrasound. Prenatal screening usually is a first step that may lead to prenatal diagnosis. There are three major reasons for prenatal diagnosis: (1) intrauterine therapy which exists for some conditions; (2) to have an option to terminate the pregnancy if that is what the parents wish to do, and (3) the parents know the health status of the foetus.
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Methods of prenatal diagnosis must be safe and effective. The standard method for diagnosis in the high risk group is amniocentesis at about 15 weeks of pregnancy. The result of the karyotype is rarely incorrect. The fetal loss rate attributed to amniocentesis has been estimated at 0.3 -0.5%. Before 15 weeks of pregnancy, a transabdominal or transcervical chorionic villus sampling may be performed, but the diagnostic accuracy is lower than that of amniocentesis and the fetal loss rate depends on the expertise of the operator, and so may be slightly higher when the procedure is not limited to expert centres. 12 (1) Screening on fetal cells in maternal blood: Fetal cells can be identified in the maternal circulation and techniques such as fluorescent or magnetic in situ hybridization can be used to identify aneuploidies, including Klinefelter syndrome, Down's syndrome and trisomy 13 and 18. It has been suggested that cells can be adequately sampled between 10 and 18 weeks of pregnancy. Screening on fetal cells in maternal blood may in the future be of value in screening. A study showed that examination of fetal cells from maternal blood may provide a noninvasive prenatal diagnostic test for trisomy 21 with the potential of identifying about 60% of affected pregnancies. 13 Screening on fetal cells in maternal blood is in its early stages. Currently, it cannot be of practical use before several requirements are met, namely: (1) adequate enrichment of fetal cells in the sample; (2) unequivocal distinction between fetal and maternal cells; (3) accurate methods for single cell diagnosis; and (4) acceptable cost. 12 Given the rarity of the most successful fetal cells (nucleated fetal red cells) in maternal blood, sophisticated techniques are required to obtain an adequate sample of these cells for analysis. The techniques available do not have the performance, simplicity, or economy needed to replace existing methods yet. 14 (2) Maternal serum screening: In 1972 raised amniotic fluid alpha-fetoprotein (AFP) was shown to be associated with open neural tube defect pregnancies. 15 In 1983, it was shown that low maternal serum AFP was associated with Down's syndrome. This association was found to be independent of maternal age. Then, raised maternal serum human chorionic gonadotrophin (hCG), and low unconjugated oestriol (uE3) were found to be markers of Down's syndrome. These two markers, together with AFP and maternal age, formed the basis of the 'triple test'. In 1987, the American Society of Human Genetics (ASHG) published a statement about issues that affect maternal serum AFP programmes and quality control for laboratories performing maternal serum and amniotic fluid AFP assays. The ASHG emphasized the following points: (1) potential applications of MSAFP were still unfolding. Therefore, ongoing educational programmes were needed for providers of obstetrical care and for patients. Counselling of patients regarding MSAFP should begin early in pregnancy so that their decision is informed and unhurried; (2) providers should educate patients about the MSAFP potential and allow patients to make decisions concerning participation in screening and in consequent steps in the management of the pregnancies; and (3) MSAFP screening should only be undertaken in conjunction with a competent laboratory. The three biochemical markers have been widely adopted and used to detect neural-tube defects and chromosomal aberrations. Triple test determines the probability (with 85 -90% accuracy) of the presence of anencephaly or spina bifida or (with 60 -65% accuracy) of the presence of fetal Down syndrome. Strategies for a more efficient Down's syndrome screening include the use of markers such as dimeric inhibin-A, hyperglycosylated hCG and beta-core fragment of hCG, as well as first-trimester screening, particularly with PAPP-A and free beta-hCG. 16 A number of papers have compared the effectiveness of different combinations of these markers. Some recommend MSAFP, total hCG and uE3, while others advocate MSAFP and free beta-hCG. In 1997, triple test was considered as being the most efficient method of screening based on the information available and the most equitable, ensuring that women with the highest risk are offered an amniocentesis. 12 Hyperglycosylated hCG has been considered as being an effective replacement for hCG and may be used as a screening test for aneuploid pregnancies. 17 The introduction of the triple test screening has raised the problem of proper counselling expectant mothers before and after the test. The inability of health professionals ordering the test of explaining abnormal triple test outcomes correctly has been documented in several studies. 18, 19 More efforts have been recommended in order to reduce unreasonable maternal anxiety by adequate counselling.
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(3) Ultrasound screening: Ultrasonographic assessment of the fetus is a routinely used screening tool for the presence of congenital anomalies. Most major structural malformations can be detected. 21, 22 It has been argued that there is no evidence for a harmful effect of diagnostic obstetric ultrasound. The main limitations of the technique are its dependence on the skill of the operator and the quality of the equipment. Its main risk is misinterpretation of the image, leading to failure to detect abnormalities or to abortion of a healthy fetus. In European countries, detection rate of severe congenital anomalies varies from 28 to 60% according to the skill of the operators.
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Fetal nuchal-translucency thickness, measured by ultrasonography at 10 -14 weeks of gestation is a marker of risk of chromosomal anomaly. Selection of the high-risk group of trisomy 21 for invasive testing by this method and by well-trained professionals allows the detection of about 80% of affected pregnancies. 24 Other results have shown that screening for fetal aneuploidy by nuchal-translucency measurement can be effective as part of routine antenatal care in an unselected population. 25, 26 At the population level, effectiveness should increase by enhancing education and training and the systematic referral for fetal anomalies screening to accredited laboratories. In addition to the increased nuchal translucency association with aneuploidy, multiple studies have now identified increased nuchal translucency as a nonspecific marker of a wide range of fetal structural abnormalities, to include congenital diaphragmatic hernia, cardiac defects, and various genetic syndromes. However, further evaluation is required to assess the role of nuchal-translucency screening in the general population when measurements are made by untrained professionals. 27, 28 The advance of the capacities of ultrasound screening raises both ethical and psychological issues. The primary goal of ultrasound screening was to observe the development of the pregnancy to the best of mother and child and for birth management, but with increasing quality of the technique and experience of the investigators abnormalities of the fetus became evident. Consequently, the difficulties of counselling expecting mothers appear: most women being offered an ultrasound scanning are at low risk of fetal abnormality and they believe that the test is designed above all to confirm gestational age, not to detect a range of abnormalities. There are important differences in the information provided before scanning, in the types of tests available, and in the amount of counselling provided before, during, and after such tests. Research suggests that many women are not told beforehand of the first scan's potential to detect fetal anomalies. 29 Many women whose pregnancies may have naturally ended in spontaneous prenatal loss are thus being faced with having to make an active and quick decision about whether to continue with their pregnancy. There is also no firm evidence that early termination is psychologically advantageous to women who undergo this procedure for fetal abnormalities. 29 For the ultrasound operators, since increased translucency may also be associated with other chromosomal abnormalities, cardiac abnormalities and a number of genetic syndromes, this may create a dilemma if the woman has declined nuchal assessment. Several recommendations have been made to improve clinical practice in prenatal testing. Staff training in providing clear and accurate presentation of all available information to all women before ultrasound screening is paramount to ensure that consent is truly informed. Careful consideration may need to be given to the way psychological support is offered in order to improve uptake of counselling services.
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(4) Screening on fetal cells obtained by amniocentesis or CVS: Prenatal diagnosis for chromosomal disorders is now widely offered to high-risk groups, either defined on the maternal age or using risk calculations based on serum marker screening test results or measurement of the nuchal-translucency, or a combination of the three. Most women at risk of carrying an affected fetus with a chromosomal disorder are offered an invasive prenatal diagnostic test. Those tests, amniocentesis and chorionic villus sampling (CVS) carry a risk of procedure-related fetal loss. Some professionals feel justified to offer all the available diagnostic tests to make an optimal use of the fetal cell sampling. 30 The same approach apply to fetal cells obtained for the prenatal diagnosis of a Mendelian disorder: a systematic karyotype is often also offered, representing a systematic screening of chromosomal anomalies. The history of genetic disorders in different populations is an important consideration in deciding which disorder to screen. (5) Preimplantation genetic screening: Preimplantation genetic diagnosis (PGD) represents an additional prenatal service for couples at high genetic risk and it may become more widespread in the future. Since the first births were reported using preimplantation genetic diagnosis, 31 it is now performed in many countries.
PGD involves testing one or two cells taken from a recent embryo of eight cells produced by in vitro fertilization, and selective transfer of embryos. This procedure is applied mainly for X-linked disease but also for a variety of other chromosomal and single-gene defects. 32 The Evolving knowledge of the genetic basis of a variety of common diseases has created possibilities for presymptomatic detection of late-onset diseases such as familial hypercholesterolemia and hemochromatosis. Screening for late-onset diseases at birth, although increasingly possible, has never been recommended, because preventive treatments often do not exist or, if available, are best carried out later in life. 38 Genetic counselling of parents regarding the risk of a disease in a child that manifests itself many decades later is rarely requested or considered. 37 Screening for late-onset diseases raises complex ethical issues with regard to informed consent, privacy of genetic information and confidentiality of test results. In addition to screening newborns, there are other strategies for identifying genetic disorders. Screening for heterozygous carriers of autosomal recessive diseases is aimed at identifying carriers who are at risk of having an affected child if the other parent is also a carrier. Such screening can be conducted before pregnancy in order to allow a wide choice of reproductive options, including avoidance of marriage to another carrier, having no children, or the use of a sperm donor, in addition to antenatal diagnosis with elective termination of pregnancy or accepting the risk, and PGD.
For instance, carrier screening programmes for hemoglobinopathies have been in place in several countries for over 20 years; these programmes have been very effective, as indicated by increasing knowledge on thalassemia and uptake of prenatal diagnosis by the target population. 39 (For this reason, it has been decided that the issue of screening for hemoglobinopathies will not be addressed in the present document.)
(1) Neonatal screening for CF: CF is the most common lethal inherited metabolic disorder in white population. The prevalence is approximately 1 in 2500 live births in populations of Western European origin. CF is characterized by severe respiratory problems and inadequate pancreatic function, caused by accumulation of sticky mucus. In total, 10 -15% of newborns with CF require medical intervention to resolve meconium plugs. Most men with CF are sterile. There is no cure, but improved treatment in recent years has increased the average life expectancy to about 30 years. 40 Intense respiratory management by inhalants, antibiotics, physical therapy, and enzyme supplements improves survival. Knowledge of the gene defect has opened up new lines of research, which may in time result in quite new forms of treatment. Clinical studies on anti-inflammatory agents are underway. CF is caused by mutation of the gene encoding the CF transmembrane conductance regulator (CFTR). More than 1000 CFTR gene mutations have been identified; few mutations account for a large proportion of mutations in selected populations. Prevalence of different mutations varies according to the ethnic composition of populations. There is no simple correlation between the nature of the mutation and the severity of lung disease, although some mutations result consistently in milder pancreatic disease. 41 Neonatal screening for CF is available through dried blood analysis for immunoreactive trypsinogen (IRT). Some recommend combination of IRT, sweat test and genetic mutation analysis for primary or recall testing. The overall sensitivity of neonatal screening is about 85 -90%. The rationale for neonatal screening for CF is that very early detection and treatment may improve clinical outcomes for children with CF, 42 but the evidence for this is currently controversial; the ability of screening to alter long-term prognosis has not been conclusively proven. 43 -47 Nevertheless, there is some circumstantial evidence favoring a benefit: screening spares parents the anxiety experienced in the time between the onset of symptoms and diagnosis; screening may also prevent a second affected pregnancy if parents are aware of their genetic status before conceiving another child. An alternative would be to train the pediatricians and the general practitioners about the necessity to test for CF any infant with a failure to thrive. This approach would be likely to pick up most of the cases with a significant clinical course. Neonatal screening for CF is currently practised in some countries like in Italy or in the UK in some regions. 48 In
France, it has been asked that health authorities implement a 3-year pilot state-based neonatal screening programme (Farriaux 1999). However, it has been suggested that more research should be carried out on the benefits of neonatal screening. Recommendations for future research include:
(1) more research on psychological and medical consequences for carrier detection in neonatal screening; (2) neonatal screening programmes to undertake RCTs of specific early treatments; and (3) audit procedures to ensure that parents give informed consent to neonatal screening. 43, 49, 50 (2) Neonatal screening for DMD: DMD is characterized by a rapidly progressive muscle weakness. This is the most frequent X-linked childhood disorder. The disease is frequent in all world populations. Prevalence at birth for DMD is B1:3500 male births worldwide and B1:5000 in developed countries that provide genetic counselling. In B70% of the cases, female subjects are carriers of the disease and only rarely develop symptoms. About 30% of reported cases are new mutations. The age at which clinical symptoms of DMD are first noted is usually between 2 and 5 years. In all affected youngsters the disease progresses steadily with no remissions. The lifespan is B20 years. There is no known treatment of DMD. Treatment is palliative (individualized physical therapy), aimed at managing the symptoms in an effort to optimize the quality of life. Assisted ventilation may improve respiratory mechanics and prolong the lifespan.
The dystrophin gene was cloned in 1986. Three different tests are performed to diagnose DMD: (1) creatine kinase (CK) test; (2) muscle biopsy; and (3) DNA testing. 51 Until recently, a diagnosis of DMD was established markedly on the basis of the clinical picture, the course of the disease, the increased activity of the enzyme CK and histological findings. DNA testing coupled with analysis of the protein involved has made the distinction between DMD and Becker muscular dystrophy possible. Genetic counselling and prenatal diagnosis have to some extent lowered the prevalence of DMD. The disease can also be detected soon after birth in babies where there is a positive family history.
Even if testing at birth is controversial since there is no advantage for newborns, which is a critical prerequisite for screening, neonatal screening has been recommended so that parents can receive genetic counselling about future pregnancies. 52 Parents can be advised about the genetic risk of recurrence, information that otherwise might not be available until a diagnosis is made at a later date. 37, 53, 54 (3) Screening for fragile X syndrome: Fragile X syndrome is the most common cause of mental retardation from a single gene defect, transmitted in an X-linked semidominant fashion. 55 The latest population prevalence figures are about 0.25 per 1000 male subjects and 0.12 per 1000 female subjects. About 6% of institutionalized individuals with mental handicap have the syndrome. The major features are learning disability of varying severity, behavioral problems such as hyperactivity and autistic tendencies, and physical characteristics. Although fragile X syndrome is not curable, there are a number of medical, educational, psychological and social interventions that can improve the symptoms. However, this syndrome is still not recognized and underdiagnosed: many at-risk families are not aware of their risk and there is no reliable estimate of the prevalence of women who are carriers of fragile X premutations. 56 The responsible gene, FMR-1, was identified in 1991 and includes a trinucleotide repeat sequence. The mutation is characterized by hyperexpansion of the repeat sequence leading to downregulation of the gene. In male subjects, an allele with repeat size in excess of 200, termed a full mutation (FM), is always associated with the affected phenotype, whereas in female subjects only half are affected. Individuals with alleles having repeat size in the range 55 -199 are unaffected, but in female subjects the sequence is heritably unstable so that it is at high risk of expansion to an FM in offspring. This allele is known as a premutation (PM) to contrast it with the FM found in the affected individual. The number of CGG repeats in a PM is potentially unstable and can increase into the FM range in a child that inherits the affected chromosome from its mother. The chances of a PM in a mother expanding to an FM in her child have been estimated at about 10% in the general population and about 60 -80% in known fragile X families. In contrast to the potential instability of a PM transmitted from the mother, a PM transmitted from the father does not expand to an FM in his daughters. 57 Among the screening tests, cytogenetic methods are unsuitable for screening purposes. Southern blotting of genomic DNA can be used but is inaccurate in measuring the size of small PMs, there is a long laboratory turnaround time, and it is relatively expensive. The best protocol is to amplify the DNA using polymerase chain reaction on all samples, and when there is a possible failure to amplify, a Southern blot. 57 A procedure that uses the automatic laser fluorescent (ALF) sequencing apparatus and reduces the number of samples that need to be analyzed by Southern blotting appears suitable for large scales screening of female subjects at-risk of carriers for fragile X syndrome. 58 A number of possible options for genetic screening for fragile X mutations have been discussed. They fall into two groups: screening to detect women who have the FM or PM alleles and screening to detect affected individuals. In the first group, possible screening strategies are: cascade screening, antenatal and preconceptional screening. Pilot programmes have reported that cascade screening has been well-received and has offered reproductive choice to families affected by this disease. In Australia, it has been reported that the birth prevalence of fragile X syndrome has decreased from 1 in 4000 male subjects to 1 in 10 000, 59 while in the Netherlands, a simulation model for studying the consequences of cascade testing for fragile X syndrome shows that cascade testing is effective in detecting carriers only if several generations are tested. 55 According to the authors, to detect 90% of all PM and FM carriers at least eight consecutive generations need to be tested. In UK, cascade screening has been recommended, although there should be a national audit of current practice. 57 Antenatal screening also provides an effective way of identifying carriers. It is well accepted and has a favorable cost-savings balance but put the couples in the situation of having to make a decision under time pressure. In Finland, it has been suggested to incorporate this screening strategy as a routine part of antenatal care in general practice. 60 With this approach, it is possible to reach the largest possible population and offer this option to virtually all pregnant females. 58 Preconceptional screening allows adequate time for genetic counselling and eliminate any adverse consequences that might result from receiving distressing news during pregnancy. It also offers at-risk couples more reproductive choices. However, it has been argued that this would be difficult to practice, since most women carriers of fragile X syndrome are not well informed of their risk. 57, 60 In the second group of options for genetic screening for fragile X syndrome, that is to say screening to detect affected individuals, the screening approaches (neonatal and pediatric screening in high-risk groups) raise questions on the justification of diagnostic testing in individuals who are suspected as having the syndrome. As there is no cure, there may be little value in accurate diagnosis. The debate against screening has centered around the potential stigmatization of fragile X syndrome patients. It has been argued, however, that accurate diagnosis allows appropriate treatment to be offered for the behavioral and educational difficulties associated with the syndrome. In addition, if fragile X syndrome is diagnosed, screening in other family members can allow them to make informed reproductive decisions on the basis of their genetic status. 57 Before implementing a population-based screening programme, studies should be carried out to establish a reliable prevalence of the disease as well as to assess the feasibility of routine screening and the emotional and social consequences of being identified as carrying a premutation. 57 In USA, the American College of Medical Genetics (ACMG) 61 recommended in 1994 that diagnostic testing should be offered for individuals with symptoms suggestive of fragile X syndrome, individuals who have a family history of learning disability and who seek reproductive counselling, and pregnant women who are known to have a premutation. The report did not recommend population screening for fragile X mutations except in the context of research. Cascade screening is already conducted in many regions, but not on a systematic basis. (4) Screening for familial hypercholesterolemia: Genetic screening for familial hypercholesterolemia may be appropriate since risk of early coronary artery disease (CAD) is considerably increased by the mutation of a single gene. 62 -64 Familial hypercholesterolemia is an autosomal dominant disorder characterized by elevation of serum cholesterol bound to low-density lipoprotein (LDL). Mutations in the LDL-receptor gene on chromosome 19 cause this disorder. Plasma cholesterol is elevated at birth, and cholesterol tends to deposit in the walls of arteries causing atherosclerosis and consequently, cardiovascular disease (heart attack, stroke) potentially fatal in patients after 30 years old. The disease is diagnosed on the grounds of clinical and biological signs, but genetic diagnosis formally identifies the causative factor. One in every two people can be affected in a family where one individual has been identified as having familial hypercholesterolemia due to a mutation of the LDL-receptor gene. Once the diagnosis is established, drug therapy (adapted for each age and case) brings the levels of plasma cholesterol back to normal and may cause atherosclerosis to regress, thus preventing potential cardiovascular complications. The heterozygous patients are generally treated in the same way as patients in the general population with a high cholesterol rate. Curing homozygous patients is more difficult because they express little or no activity from the LDL receptor and they are resistant to most cholesterol-lowering drugs. The prevalence of familial hypercholesterolemia is of 1/500 in Western societies. The homozygous FH is very rare, occurring with the frequency of about one in a million. DNA testing is the best way to diagnose familial hypercholesterolemia. 65 It is appropriate in particular when (1) physical signs or family history are equivocal or absent (important given the increased risk of CAD associated with FH compared to other hypercholesterolemias) and (2) when there is a family history of premature CAD, especially in immediate family members. 62 A positive DNA-based test for a mutation is especially useful in children, in whom plasma lipid levels may not be diagnostic. According to the British Hyperlipidaemia Association, selective screening based on a family history of familial hypercholesterolemia or premature coronary artery disease is an appropriate strategy for identifying most children with familial hypercholesterolemia. 66 Drug treatment of children with FH is advisable because of the better possibilities to make a definite diagnosis and the early occurrence of coronary heart disease. However, children should not usually be screened before the age of 2 years. Even if screening for FH in childhood can help to save lives through preventive treatment and therapeutic interventions, screening of children remains controversial. 67 A pilot study in UK showed that parents' responses to screening vary according to perceptions of the underlying cause of the positive screening test result. When parents perceive the test as detecting raised cholesterol, the condition is perceived as familiar, dietary in origin, controllable and less threatening. When the test is seen as detecting a genetic problem, the condition is perceived as uncontrollable and, hence, more threatening. 68 Appropriate genetic counselling must accompany risk assessment, genetic testing and screening for familial hypercholesterolemia. 69 Population-based genetic screening for FH in not practical because of the large number of mutations causing this disorder. 70 However, in some populations most cases of FH can be explained by only one or a few mutations. Examples include the Finns, the French Canadians, and the Christian Lebanese. In these populations the frequency of FH is higher than that generally accepted in Western countries (of one per 500). 70 As the number of the LDLreceptor mutations increases, the preferential geographical distribution of some of them has become apparent. Geographical associations for LDL-receptor genes have been reported in the west of Scotland and in the Netherlands.
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(5) Screening for hemochromatosis: Hemochromatosis is a disorder of iron metabolism that increases iron absorption and results in excessive iron accumulation. Clinical manifestations range from lethargy and abdominal pain to arthropathy, diabetes, hypogonadism, skin pigmentation, cardiomyopathy, and hepatic fibrosis and cirrhosis. There is a high morbidity and mortality associated with untreated hemochromatosis. Clinical manifestations appear in the 40th to 50th decade in men, later in women owing to the protective effect of blood loss from menstruation and childbirth. Symptoms of iron overload are occasionally observed in young men and women (by the age of 20 years). Early symptoms are multisystemic and nonspecific. Early diagnosis and treatment before the occurrence of organ damage improves prognosis. 72 Among symptomatic individuals, iron depletion treatment can improve some, but not all, clinical manifestations. Periodic phlebotomy to remove the excess iron is necessary to threat the condition. For a subject who has no evident tissue or organ damage, the long-term outcome and life expectancy with proper management of the disease equals that for people who do not have iron overload. For a subject who has evident tissue or organ damage, further damage can be halted, but damage already incurred usually cannot be reversed. Hemochromatosis is the most common genetic disorder in Caucasians. The prevalence is approximately of 1/300 and 1/9 people is a carrier. A candidate gene on chromosome 6, HFE was identified in 1996. 73 One mutation, C282Y, has been detected in as many as 11% of northern European white individuals tested. 74 About 70% of men and 40% of women who are homozygous for hemochromatosis develop clinical manifestations at some point in their lives. Heterozygotes are usually asymptomatic. Another mutation, H63D, appears to act synergistically with C282Y in about 3 -5% of patients with typical hemochromatosis. 75 It is becoming accepted that subjects should be tested for both C282Y and H63D mutations as a proportion of compound heterozygotes do express clinical disease. Among the screening methods, the biochemical screening test, serum transferrin saturation, identifies about 70% of men and 60% of women with hemochromatosis at a 0.3% false-positive rate. DNA-based testing for C282Y homozygosity identifies about 83% of individuals with clinically diagnosed hemochromatosis. 76 The false-positive rate is likely to be very low. Indications for DNA testing include:
(1) previous clinical diagnosis of hemochromatosis; (2) positive family history or partner with hemochromatosis, especially if Cys282Tyr positive; (3) elevated transferrin saturation or serum ferritin concentration; (4) unexplained elevation of serum liver enzymes; (5) cirrhosis, liver failure, or hepatocellular carcinoma; 6) diabetes mellitus; and (7) nonspecific compatible symptoms and signs: fatigue, abdominal pain, hepatosplenomegaly, joint pain, cardiac arrhythmia, congestive heart failure, impotence, hypogonadism, hypothyroidism and hyperpigmentation. Screening for hemochromatosis using transferrin saturation involves relatively modest costs that may be recovered if complications of hemochromatosis can be prevented by early detection and treatment. 77 The most cost-effective strategies utilizes transferrin saturation for initial screening, followed by DNA testing. 78 Reduction in the cost of transferrin saturation would lead to a significant reduction in total screening costs. Additional benefits of a screening programme include detection of other iron overload disorders and iron deficiency. However, screening is not commonly conducted as part of routine medical care or check-ups. The available screening tests are imperfect. While they can identify many persons at increased risk for hemochromatosis, the proportion that will develop serious clinical manifestations related to iron overload is not known with certainty and DNA-based tests do not provide a simple resolution to these questions. 79, 80 Before implementing a population screening programme for hemochromatosis, further research is needed for (1) evaluating the penetrance and preventable disease burden, laboratory standardization, and optimal strategies to minimize potential risks of screening for hemochromatosis; and (2) evaluating the benefits and prevention-effectiveness of population-based screening. 80 -82 Moreover, the size of the effect of screening on reducing morbidity and mortality is uncertain, as well as the best age for screening in men and women. 83 Guidelines and policy development have been published. Some consider that population-based genetic screening for hemochromatosis is not justified at present, due to uncertainties about prevalence and penetrance of HFE mutations and the optimal care of asymptomatic people carrying HFE mutations. Tests for HFE mutations may play a role in confirming the diagnosis of hemochromatosis in persons with elevated serum iron measures, but even this use is limited by uncertainty about genotypephenotype correlations. In addition, use of a genetic screening test raises concerns regarding possible stigmatization and discrimination. 80, 82, 84 In France, a report published by the National Agency for Accreditation and Evaluation in Health (ANAES) concludes that it appears premature to propose a systematic screening insofar as there are still numerous medical uncertainties, the economic aspects have not been calculated, and the individual psychological repercussions are difficult to foresee. 85 However, since hemochromatosis is a real public health problem, certain initiatives should be taken to produce answers to a series of questions. 86, 87 On the other hand, the College of American Pathologists states that in view of the high prevalence in the American population (prevalence varies with ethnic background), the low cost of diagnosis and treatment, the efficacy of treatment if begun early, and, on the other hand, high costs and low success rate of late diagnosis and treatment, systematic screening for hemochromatosis is warranted for all persons over the age of 20 years. The initial screening should be by measurement of serum iron concentration and transferrin saturation. The practice guideline provides a diagnostic algorithm for cases in which the serum transferrin saturation is 60% or greater. It also provides guidelines for clinical management. 88 (6) Screening for cancer susceptibility: Cancer mortality rates have risen throughout most of this century in developed countries, and a downward trend has just emerged in recent years. Nevertheless, it is predicted that cancer will soon be the leading cause of death among the Westerners. All cancer can be described as due to altered DNA. Many of these mutations will be accumulated during the normal division of somatic cells. However, some people may inherit abnormal genes, which predispose those individuals to high risk of certain malignancies. These individuals can sometimes be identified by having a family history of affected individuals, some of which might have early age of onset or multiple malignancies. Specific genes have been identified as being associated with certain of these malignancies. The hereditary cancers include ovary, breast, colon, endometrium, and to a lesser extent, prostate, skin and pancreas. 89 Some of these cancerpredisposing genes are highly penetrant with up to 50% of gene carriers developing the associated malignancy within a 70-year life expectancy. 90 Molecular testing for the presence of cancer-predisposing genes is available for many of the hereditary cancers. While there is currently no way to correct a mutant gene, early detection and some techniques of chemoprevention are of clinical value. People who fear that they are at high risk and learn that they are not can benefit from the relief of anxiety through the genetic counselling process. 91 The study of inherited conditions predisposing to cancer has led to major discoveries on the basic mechanisms of carcinogenesis. Those investigations have permitted to discover a new class of cancer genes now named 'suppressor' genes (or antioncogenes), and to demonstrate their implication in the majority of cancer including the sporadic one's. 92 Those studies have indicated that familial forms of cancer can also result from alterations of a set of genes controlling genomic stability. In clinical practice, the identification of the molecular basis of major forms of inherited predisposition to cancer, has allowed to define those cancer syndromes better. As a consequence, it appears now possible to propose to the at risk individuals, and their families, screening protocols based on precise estimate of their genetic risk. 93 However, the rapid advances in molecular technology are a direct challenge to the medical community and cancer centers to supply specialized clinical services. Detection and prevention of certain malignancies are impeded because few medical practitioners know of these tests, and because patients fear the emotional consequences of testing. The need for genetic counselling will increase as more families with inherited cancer are identified, more cancer genes are isolated, and genetic analysis becomes more available.
In the USA, the American Society of Clinical Oncology (ASCO) 94 recommends that cancer predisposition testing be offered only when: (1) the person has a strong family history of cancer or very early age of onset of disease;
(2) the test can be adequately interpreted; and (3) (7) Carrier screening at antenatal clinics: Carrier screening programmes attempt to detect individuals who carry a disease-related allele in order to inform them about their specific risk and help them make reproductive choices accordingly. Carriers are phenotypically normal and show no signs of the disease, but such individuals would be at risk for having children with the disorder. 6 Carrier screening for recessive diseases is initiated during pregnancy. If the result is abnormal, tests of the male partner follow. If both partners are carriers, they are informed of the possibility of a test on the fetus. If prenatal testing is performed and shows that the fetus is affected, the parents can decide whether to terminate the pregnancy. Carrier screening at antenatal clinics has reportedly been well-received. 103 Although reduction in birth prevalence is not the aim of such a programme, it has been reported that screening for heterozygosity during pregnancy has led to a marked reduction in the frequency of thalassemia major in several Mediterranean countries as well as in the UK and of Tay-Sachs disease among Ashkenazi Jews in the United States and elsewhere; screening for sickle cell carriers is very well accepted, but the uptake of prenatal diagnosis is lower for sickle cell anemia than for thalassemia. 37 Screening for carriers of CF has been recommended. In 1997, in the USA, the ACMG recommended that couples in which one or both reproductive partners either has CF or has an affected relative should be offered carrier testing and counselling. 104 The NIH Consensus Statement on Genetic
Testing for Cystic Fibrosis 50 also recommends that genetic testing for CF be offered to adults with a positive family history of CF, to partners of people with CF, to couples currently planning a pregnancy, and to couples seeking prenatal care. In UK, the introduction of routine antenatal screening for CF has been recommended. 43 The report suggests that screening should also be available for infertile men and for sperm donors. Testing should be carried out in laboratories with a high throughput of CF tests. Carrier screening at antenatal screening has been proposed also for Fragile X syndrome in Finland and in UK. 57, 60 In UK, carrier screening at antenatal clinics for hemoglobin disorders is standard practice. However, the UK Confidential Enquiry into Counselling for Genetic Disorders has shown the need for a national policy on screening for hemoglobin disorders, aiming to offer prenatal diagnosis in the first trimester in all pregnancies at risk, and including ongoing audit. 105 For most recessive conditions, we have no consensus as to which specific carrier screening programmes should be carried out. With the progress that is being made in mapping the human genome, public health applications can be developed which will make it possible in the near future to detect carriers of many recessive gene defects. It has been suggested that carrier screening should at least be considered by those women registering for CVS or amniocentesis. 60 (8) Preconceptional carrier screening: Some autosomal recessive diseases are often restricted to certain ethnic or racial groups, such as the thalassemias, sickle cell anemia, and Tay-Sachs disease. Population screening for heterozygous carriers is aimed at identifying carriers who are at risk of having an affected child if the other parent is also a carrier. In communities where the risk of serious genetic disorder is high, preconceptional carrier screening may be desirable. 106, 107 In fact, preconceptional carrier screening offers at-risk couples more reproductive options, as well as provide sufficient time to discuss these options. Its allows adequate time for genetic counselling and eliminate any possible adverse consequences that might result from receiving distressing news during pregnancy. However, preconceptional carrier screening is difficult to practice because reaching of the target group is difficult. For example, clinical trials for CF have shown that many adults say they prefer screening before conception but do not see a physician for evaluation before conception and providers find screening more readily accomplished in the setting of a prenatal visit. 108 To improve preconceptional carrier screening, the organization of adequate facilities to meet the demand for screening and prenatal diagnosis before the beginning of the educational campaign is essential. 106, 107 A continual monitoring of population responses of what the providers have to offer is another factor affecting effectiveness of screening. Involvement of the population has the advantage of preparing efficacious and simple messages but also of avoiding potential adverse effects on carriers and parents, as well as to be responsive to the cultural values and religious beliefs of the target populations. 106, 107 Cascade screening is also appropriate because people learn by experience. Screening for CF before pregnancy has been proposed. 109, 110 Costs considerations are not an obstacle, on the contrary it has a favorable cost-savings balance. 47 However, studies have reported that this type of screening presents logistical difficulties and that advantages, such as opportunities for adoption, had not been shown (J Med Screen 1996;3:55). Much attention seems to be required for provision of information at all stages of the screening procedure. 43, 46 In other respects, testing should be carried out in laboratories with a high throughput of CF tests.
Regional variations A survey made by the EUROSCREEN Group, a Biomed Project of the European Union, shows that there are no genetic screening programmes common to all western European countries. 111 Neonatal screening for phenylketonuria is routine in all countries except Finland. The age cutoff at which amniocentesis is offered routinely varies between countries. Screening based on maternal age alone tends to be replaced by maternal serum screening. Regional variations seem to be due to genetic disease patterns and to the novelty of genetic services: Finland has a different pattern of genetic disease from the rest of Europe, selective abortion following testing is not legally acceptable in Ireland, and in Germany the subject of the discussion of genetics and biotechnology is controversial. Regional variations also seem to be due to general factors such as a lack of knowledge of genetic disorders, which is seen as a barrier to informed consent and the fact that those giving informed consent may not be those who will be directly involved in the consequences of the test; which is, parents give consent for a young child. In Germany, although an obligatory newborn screening is established for congenital hypothyroidism, galactosemia and phenylketonuria, in Bavaria the parents have to agree and are allowed to refuse from this programme.
Current legislation
The principles that need protection seems to be the 'right not to know' and the right not to have others know about genetic traits: protection against logically straining effects from predictive genetic information and protection against genetic discrimination and stigmatization. 112 How then to guarantee these protections? Different forms of protection may each play a part: information and education, scientific measures regarding the quality and relevance of the tests, codes of conduct, regulation through informal or formal law. Concerning the latter, when there is awareness that a development in society, although beneficial in some respects, could be harmful in others in that it may interfere with individuals rights, usually the call for legislation makes itself felt. However, it has been argued that by enacting laws which are designed to resolve only issues of genetic discrimination and stigmatization, there is a chance that other questions will not addressed. 112 In addition, there is little evidence of consistency between the various national laws and the supranational provisions either do not address the issue directly or do not contain enforceable sanctions. 113 Ten western European states have enacted legislation or established a procedural regulatory framework that addresses the issues of genetic screening; either by laws explicitly targeted at screening (Austria, France, The Netherlands, Norway) or by laws that have indirectly an impact on the use of genetic screening techniques (Belgium) or by a procedural system of regulation which can adjust to any changes in technology (Germany, Sweden, The United Kingdom) (see Appendix A). The last method of regulation would be unpredictable and uncertain in posing problems for commercial ventures who would prefer to assess the regulatory climate in the mid to long term before they launch a particular product. 112 Many other stake-holders (insurance companies, employers, patients) claim the freedom to use genotyping and genetic screening without significant legal restrictions.
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Although several European countries have prepared legislation relating to particular aspects of genetics (embryo research, genetic screening, use of genetic tests in employment and insurance), it appears that in general, the response would seem cautious: legislation in the field of genetics is hard, such as the pace of developments and the difficulty of assessing their social consequences. Other problems are the similarity or the difference between genetic information and conventional medical information. It has been proposed that the response of the law would be to monitor rather than to ban and self-regulation by guidelines or codes of conduct should be preferred to statutory regulation; at international level, common principles should serve as a common framework for adequate national policies. 111 Some issues can be regulated at the national level, but international regulations seem to be preferred for several reasons: the development in genetics is an international one, affecting individuals in all countries, which creates a common responsibility concerning possible harmful consequences. Fundamental divergence of national legislation may have adverse effects on international scientific cooperation and the mobility of health professionals and patients across frontiers. For others, international regulation may enlarge the protection and provide further equality.
The tables below list the current legislation, policy statements, or professional guidelines addressing directly and indirectly the issue of genetic screening. Table Continued Instances Jurisdiction
Population genetic screening programmes B Godard et al
S64

European Journal of Human Genetics
Special issues
From family testing to cascade screening to population screening Family testing, which is genetic testing from an index case to relatives, is a current practice in medicine.
Individuals may wish to be tested if there is a family history of one specific disease, they show symptoms of a genetic disorder, or they are concerned about passing on a genetic problem to their children. For those whose test results are positive the decision about whether to suggest tests to relatives is left to their discretion. Genetic testing is increasingly being offered to family members at all stages of the life cycle. These tests can either be screening tests or diagnostic tests. There are two main approaches in genetic screening: screening along family lines starting from an index case (cascade screening, eg screening for familial hypercholesterolemia) and screening without taking family history into account, e.g. neonatal screening for PKU). Cascade screening involves the diagnosis of an affected individual followed by the systematic identification and testing of relatives. The impact of cascade screening is relatively low. 122 Even if the disease is known in the family, information on the genetic risk may only be disseminated to a minority of those relatives at risk or relatives may refuse to be tested and using individuals within families to initiate the contacts with distant relatives, which is necessary when cascading goes further than about the first-cousin level, is an activity that is likely to make genetic counsellors unpopular in the community. 123 But, even with these factors, it has been argued that cascade screening remains more efficient than general population screening and has the advantage that the detected carriers have, in general, better knowledge of the disease because they may know an index case. 55 Population-based screening is an alternative to cascade screening. Population-based screening is more effective than cascade screening in giving the highest number of carrier couples an informed choice about reproduction. The options are accepting the risk and just go on, refraining from biological children, with or without adoption, AID or egg cell donation, prenatal diagnosis, or preimplantation diagnosis. The experience with autosomal Table Continued Instances Jurisdiction
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European Journal of Human Genetics recessive disorders suggests that those who find themselves at risk of bearing a child with a recessive disorder is to ask for prenatal diagnosis and a monitored pregnancy. 124 The method in which screening is offered (personal invitations, mails, leaflets) is a major determinant of acceptance rates. For example, it has been reported that all the following are needed in connection with screening for the hemoglobin disorders: general information for the public and for pregnant women, posters and leaflets to encourage carrier testing, diagnosis-specific information for the carriers identified, information for couples where both partners have been tested, complete information for at-risk couples, information to patients and families about each disorder and its treatment, and guidelines for doctors on treatment and prevention as well as for service planners. 125 The likelihood that carrier screening would be closely tied to prenatal diagnosis has influenced the discussion of when to perform screening. One school of thought argues that the most effective time is during pregnancy. 60 A different view suggests that screening during pregnancy places an undesirably heavy burden of decision-making on a susceptible and captive group, and that individuals must be allowed to make up their minds about the implications of carrier status before a pregnancy.
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The Informed Consent Issue In opposition to ordinary clinical practice in which investigations are carried out on individuals with symptoms who seek medical help, in a genetic screening programme, healthy individuals are approached for investigation and a percentage are identified as being at risk of a disorder to justify an intervention.
Deciding not to take part may also have consequences. In all cases, individuals who are offered genetic screening are faced with having to make a choice. It is therefore essential that approached individuals consent to join with knowledge and understanding of the screening test, together with the limitations of the test, so that they can decide whether they wish to be screened. With very few exceptions, to comply with the law and the medical deontology, the right of an individual to take a free and informed decision on the performance of a test which may reveal in his genetic make-up the presence of a mutant gene that, whatever the result, could have an effect on his life must be respected. For that to be done, three conditions must be fulfilled: (1) sufficient understanding of the implications of a decision that implies information on the nature of the test, the significance of the results, and existing prevention and therapy; (2) freedom of choice and absence of any form of constraint; and (3) legal capacity to give a free and informed consent. 126 However, the extensive and intricate nature of genetic information, and the unfamiliarity of most people with this area, brings into doubt whether obtained consent is free and informed. Various studies have examined individuals' experiences of screening and the activities of health professionals who provide a genetic screening programme. It appears that obtaining truly informed consent for a complex test, such as MSAFP screening, is not a simple process. Participants met a few, but not all, of the criteria for informed consent. Women understood that the test was voluntary, but their comprehension of the meaning and implication of a positive test results was deficient. Despite this, they signed the informed consent document. 127 Other studies have shown that individuals have difficulties to understand the result of a CF carrier test and the risk of having a CF child. In one case, the difficulties were complicated by the limited sensitivity of the DNA test. 128 In the other case, it was the method of testing (two-step method or couple method) that affected the understanding of the implication of the test result. 129 Even when properly understood, informed consent presents an array of ongoing problems and unanswered questions. These include the question of how much information must be given to patients, and how much is too much; and how to ensure the full voluntariness of subjects' consent. 130 Sometimes more information is associated with increased understanding of the concept and sometimes divulging less information seems to be associated with less anxiety. However, it would be irrespective of consent method. There is some evidence to suggest that there is an optimal amount of information that enhances patient understanding and which might, in turn, reduce anxiety and possible harm. 131 The British General Medical Council's guidance on seeking patients' consent (1999) makes it clear that physicians must make sure that patients are provided with all the information they want or ought to have to make a properly informed decision.
The family-connection The genetic nature of a disorder often results in risk implications to family members of the person screened, even though they may not be or perhaps wish to be included in the screening programme. They may even have no prior personal experience of the disorder that may be detected. This situation has psychological consequences for the individuals and their families. Screening can give confidence and reassurance but also anxiety. Adequate counselling and the provision of information that is both balanced and accurate can play a crucial role, but the amount of counselling that can be offered to a screened population is often minimal because of the resource implications. According to The Health Council of the Netherlands, 116 before implementing a genetic screening programme consideration must be given to whether the principle of 'do not harm' justifies confronting people with choices that are often very difficult to make. Unless effective treatment is available for improving the quality of life of a person with a disorder, screening constrains individuals to make decisions about having children, lifestyle and how to live the rest of one's life. Since having certain genetic traits may not affect one's health, nor lead to the development of a disease, it is important to consider the benefits and risks of knowing whether the trait is present or not. Subsequent to being identified as a carrier, some have reported experiences with stigmatization and subsequent problems with low self-esteem. Developments of new tests may exacerbate these issues and needs further exploration. In other respects, the implications of carrier screening on family and social relationships require that the interests of the individuals be balanced against the interests of other individuals and of society as a whole. Tension can develop between the right of an individual to confidentiality and the right of other individuals to be informed of potential harms. In 1975, the American Committee for the Study of Inborn Errors of Metabolism stated that the results of screening should be disclosed to others without consent only when necessary for the patient's medical care or to protect others from risk created by the patient's condition. it has been proposed that when disclosure is considered necessary, it should be limited to the minimum necessary information. These guidelines would apply not only to individuals but also to entities such as insurers and employers that might benefit from this. 132 Multidisorders screening Advances in DNA-based diagnostic procedures have led to a rapid increase in the number of genetic disorders and mutations of one disorder for which screening is possible. A panel of rapid and economical screening tests becomes increasingly available. These tests can be used to find information about disease, carrier or susceptibility status for multiple disorders or mutations on a single pass. 133 It will then become increasingly difficult, if not impossible, to inform those offered screening about all the genetic information that can be obtained and the implications of that information. 133 In a setting of genetic screening, what is at stake is the right to decide whether or not to have a genetic test, with emphasis on the right to refuse. To respect selfdetermination and rational decision-making, it has been proposed to develop a 'generic consent for genetic screening' that would emphasize broader concepts and commondenominator issues in genetic screening. 134 The aim is to provide sufficient information to permit patients to make informed decisions about genetic screening, yet avoid the information overload that could lead to misinformed consent.
Commercialization Medical interest, patients' demand, or awareness of the available testing opportunities are factors that may lead to an increase in genetic tests market. However, given the amount of financial investment in the area, the need to maintain the confidence of potential investors, and the media hype that often surrounds a new genetic discovery, many fear that a myriad of novel genetic services will be offered to the public before the legal and social ramifications have been fully explored. 135 Concerns are expressed about the possibility of offering a test even if it is not medically indicated as well as the monitoring of technical quality, the availability of counselling and follow-up facilities, the standards of confidentiality or the costs and benefits of genetic testing services. 136 Studies have shown that the counselling and consent processes that ought to accompany commercial services have been found to be insufficient. 137, 138 Inversely, other studies have
shown that quality control of screening tests as well as quality information of direct marketing of these tests to the public have been proved for CF carrier screening in UK. 139 But the cost of the test, the difficulty of finding time for counselling and lack of consensus about the need for screening are cited as reasons for not implementing screening programmes. For some people, such arguments make private screening inevitable as they assume that the public will demand such tests. Marketing and advertising strategies used by the biotech/ pharmaceutical industry are also criticized as an inappropriate means of conveying medical information. 140, 141 Although research seems to indicate that patients support this type of advertising, health-care providers believe that it undermines the physician/patient relationship by encouraging unreasonable patient demands for services. 142 Others consider that 'commercial push may be a good way of assessing population need' because individuals get to weigh the benefits and hazards of a screening test before requesting it. 16 However that may be, if high-risk cases may be diagnosed, would it be as part of the patients' rights, it remains an unanswered question, whether or not everybody has the right to know their genetic outfit for no direct health reasons, even if paid privately. Nevertheless, there are only a few diagnostic services that are sold commercially. For example, in Europe, a large quality assessment of CFTR gene mutation testing methods shows that only a minority of the participating laboratories makes use of the commercially available mutation detection kits. 143 In UK, The Advisory Committee on Genetic Testing 144 has recommended that companies wishing to sell genetic tests through the mail be restricted to carrier testing. This approach has been found too permissive. 145 In the Netherlands, the Health Council 116 has suggested to restrict genetic tests to what is medically appropriate. Commercial tests and services offered through health-care system seem to offer the best possibilities for control and regulation. 137, 146 Advantages are better possibilities for counselling and support. Follow-up in the form of preventive measures might be easier to arrange, and in cases of prenatal tests selective abortion for conditions generally felt to be not serious could be more easily discussed. The possibility of misuse can perhaps not be avoided, but may be acceptable in view of the advantages of preconception commercial genetic carrier screening.
A case can be made to provide certain genetic tests directly to the public. 146 These should meet certain
conditions. An overseeing body in which all interested parties are represented could take on the task of deciding which tests ought to be offered through health care and which offered directly. This body could also assess their quality, the information provided and test interpretations and discuss the need for reimbursement. Reimbursement could be a means to enforce quality control or to meet other criteria.
The players on the scene 'A genetic screening programme will only be effective if it is accepted by the target population and the medical profession' said the French National Ethical Consultative Committee in 1995. 147, 148 The way in which the risk of onset of a severe illness is viewed varies in different groups and individuals. Certain diseases, although frequent, remain obscure for various reasons: no characteristic phenotypic expression (CF), secrecy observed by families (frequently occurring in cases of mental retardation, for instance fragile X syndrome), inequalities of access to genetic services particularly for minority ethnic groups or no professional consensus on the implementation of a screening program. Participation by the medical profession, in particular by primary-care physicians who are involved in interpreting results to patients and families following the encounter with the geneticist, is also essential for a screening programme to be successful. The way in which screening is offered can also influence the way in which society views people with identifiable handicaps: balanced information will ensure that they are not seen as the result of missed opportunities for prevention. Anyhow, a high rate of participation should not be a goal as such. The venue through which screening is offered may have substantial implications on the provider -patient relationship as well as on the utilization of genetic services and other medical services (laboratories, primary care clinics). Screening creates obligations to follow-up with a more specific diagnostic test, as well as a possible responsibility to recontact or update individuals as improved screening tests are developed. Information and counselling are a sine qua non. The costs and social implications of these new obligations should be factored into the decision to initiate a genetic screening programme. 6, 99 Time constraints, both lack and plethora of knowledge, low tolerance for diagnostic ambiguity can impede the physicians to meet an adequate standard of care, would it be to obtain informed consent, to provide genetic counselling or to follow patients on a long-term basis. It has been argued that the increasing use of genetic tests will render the provision of pretest counselling impracticable. 111 It is likely that counselling will be kept for positives only. Already commercial companies offer testing by post without any pretest counselling, for CF carrier status and the triple test.
In addition to medical specialists, appropriate service development also requires the formation of multidisciplinary groups, development of an appropriate infrastructure including trained genetic counsellors, and collaboration with patient support associations. 125, 105, 148 In other respects, the high degree of technicality and diversity of genetic tests implies specialized laboratories as this is an essential condition for sustained technical quality of results and of their interpretation. Procedure for habilitation and quality control must be established. A quality control trial conducted by the European Concerted Action on Cystic Fibrosis has shown that many laboratories (35%) have a percentage of errors unacceptable in a routine testing setting. In order to improve genotyping, it has been recommended to develop a consensus testing strategy for routine diagnostic laboratories and centralized mutation analysis facilities for rare or country-specific mutations in a limited number of expert centres, in combination with regular training sessions and quality assessments. 143 For tests to be performed on a vast number of people, feasibility and reliability pilot studies must be undertaken before starting. 99, 149 The results will need to be examined with discernment since a pilot study is carried out in privileged circumstances, which do not necessarily tally with those of a routine testing procedure (quality and motivation of participants, including, frequently, tested individuals themselves) (National Ethical Consultative Committee 1995). In spite of all these considerations, the stress on individual counselling raises the question of whether genetic screening should benefit the individual or society and whether these are in opposition. Currently, decisions are made by the individual or couple, although what decisions can be made may be limited by resources and legal restrictions. It was acknowledged that in the area of public health genetic screening programmes will be seen as a way of cutting costs as well as individual suffering. 111 In Denmark, it has been estimated that the future savings on health-care expenditures resulting from 1 year of neonatal screening for phenylketonuria and congenital hypothyroidism are 28 times higher than the cost of screening. 150 The authors consider that it is desirable to expand the existing screening programme to include a range of rare inherited metabolic diseases, which collectively are frequent. This seems realistic with the advent of tandem mass spectrometry, which allows cost-effective simultaneous screening for a group of inborn errors of metabolism. In Finland, screening for fragile X mutations in low-risk pregnancies has shown that if avoiding the treatment costs incurred by an affected individual is seen to be a benefit for society as a whole, then screening seems economically justifiable. 60 However, in the cases where treatment options are limited, it is recommended to have safeguards that protect individuals from pressures to adopt options, such as avoiding conception or terminating affected fetuses, just because they would be cheaper than the clinical management of an individual with the disease. 136 Evaluating genetic screening programmes Programme evaluation is supposed to provide objective information on the effects of a service in order to inform those in charge of establishing policies and allocating resources. 6 Identifying worthwhile screening programmes, developing the correct strategies, and implementing them effectively is no easy task. Monitoring, evaluation and quality control are important components for all new screening programmes. Even when the same test is used for screening and for diagnostic testing, its predictive value (proportion of persons testing positive who have the condition or testing negative who do not have the condition) will differ. Changes to sensitivity (ability of the test to detect all those who have, or who will develop, the disease), specificity (ability to classify correctly those persons who do not have or will not develop, the disease), and predictive value of a genetic test occur when moving from a population with a high prevalence to one of low. This could reflect either a lower prevalence of the disorder and a consequent drop in the positive predictive value of the test or a weaker correlation between genotype and overt disease in the general population due to ascertainment bias in the original population. 6 What constitutes a reasonable sensitivity, specificity, or positive predictive value can vary from one disorder to another and is a function of both the performance characteristics of the tests and the value assigned to a false or missed identification as compared to the benefit of identifying cases. 136 Issues of test reliability (the ability of a test to correctly assign people to a group on repeated measures and evaluates the variation due to the testing method) and validity (the ability to identify people correctly as either having, or not having, the genetic trait) need also be addressed. 99, 6 Combinations of screening techniques have been proposed in order to detect a reasonable proportion of individuals at risk for a disorder. For Down's syndrome, both first-trimester screening and second-trimester screening are effective means of selecting women for CVS or amniocentesis, but there is uncertainty about which screening method should be recommended at the population level. If several screening tests are offered sequentially during the pregnancy, the risk estimated should be based on all test results whatever their timing. 151, 152 For CF, several CFTR mutation detection methods have also been evaluated. 143, 153 The proficiency (the correct interpretation and timely, unambiguous, reporting of results) must apply within the same laboratory as well as across laboratories. 154 Consequently, reliability, validity, and proficiency measures should be regulated and assessed on a regular and continuing basis. 6 Another issue that need to be considered when extending tests from the research setting to widespread screening is that the test may not be easily adaptable for widespread use for economic reasons. 6 The cost of screening is another important issue in programme evaluation. However, it is often limited to the financial aspect, compared with that of treating an individual with the disease or estimated per disease-associated genotype detected. The cost -benefit analysis are based on technical considerations that measure the impact of programmes and how well they attain their stated objectives. 6 Although criteria for quantifying benefit may be appropriate from a scientific perspective, the perception of those being tested might differ. A much more critical approach to screening has been adopted and efforts have been made to ensure that new programmes of proven benefit and which are acceptable to the public, are effectively and equitably implemented in the community. 155 Surveys suggest that practice of screening is not uniform and that there is a lack of systematic evaluation. 156 -158 Discussion of screening has focused largely on test characteristics and performance against a gold standard with less attention being given to issues of policy formation, priority setting, implementation and quality assurance of the effectiveness, efficiency and safety of the test procedure. But without these elements, it has been reported that quality and test performance deteriorate, as recruitment and follow-up are incomplete. 156 In UK, a framework for the evaluation and implementation of national screening programmes has been set out. The aim is to ensure that screening programmes are not introduced into the National Health Services unless there is robust evidence that benefit outweighs harm. 159 For that, ideally policy decisions about new screening initiatives should be informed by evidence from randomized controlled trials but for most of the conditions for which a screening programme proposed, large trials would be needed. 160 In Scotland, suggestions have been made to improve quality and relevance of screening: (1) national guidelines should be formulated to promote the implementation of the same core screening activities in all Boards; (2) audit and quality control programmes should be universal and systematically applied; (3) the demarcations of professional and managerial responsibilities and lines of accountability should be clarified; (4) any proposed new screening programmes should be assessed in the light of the classic World Health Organization principles before their introduction. 157 In USA, the Task Force on Genetic
Testing has identified several problems affecting safety and effectiveness of new genetic tests, as defined: validity and utility of genetic tests, laboratory quality, and appropriate use by health-care providers and consumers. On the basis of these findings, the Task Force recommended 'policies that will reduce the likelihood of damaging effects so the benefits of testing can be fully realized undiluted by harm'. 136 
Discussion
The workshop organized by the ESHG (1999) highlighted the different point of views expressed by health-care providers and patients organizations on the risks and benefits that come with new genetic tests. It showed how various uptake rates are influenced by provider behavior, by how the test is offered and to whom the test is offered. It also demonstrated the scrutiny that went internationally into the efforts to safeguard new genetic testing. Arguments for and against starting screening programs have been put forward. In accordance with the Dutch Health Council definition, a genetic screening programme consists in 'any kind of test performed for the systematic early detection or exclusion of a hereditary disease, the predisposition to such a disease, or to determine whether a person carries a predisposition which may produce a hereditary disease in offspring'. It has been questioned whether genetic screening differs from other types of screening and testing in terms of ethical issues. The general impression on the future of genetic screening is that one wants to 'proceed with caution', with more active impetus from the side of patients organizations and more reluctance from the policy-makers. The latter try to obviate the potential problems about the abortion and eugenics issues which might be perceived as a greater problem than it is in reality. However, it seems important to maintain a balance between a 'professional duty of care' and 'personal autonomy'.
Genetic screening programmes before birth Genetic screening includes a wide variety of procedures. Technical limitations of these procedures as well as ethical implications have been discussed. Before birth, screening on fetal cells in maternal blood is still in its early stages. Given the rarity of the most successful fetal cells in maternal blood, sophisticated techniques are required to obtain an adequate sample of these cells for analysis. Screening on fetal cells in maternal blood will be an alternative to CVS or amniocentesis but will not replace them: women with a positive result will ask for an invasive prenatal diagnostic test before deciding for a termination of pregnancy.
Maternal serum screening participation is high. In France, although 97% of women sign a consent form before screening, only 80% appear to have received an appropriate information. Although the problem of proper counselling expectant mothers before and after the test has been well documented, it is reminded that to ensure free informed decision making whether to have a triple test or not, it is of the utmost importance to discuss the 'sequence of decisions' before the offer of the triple test. After a positive triple test result, the importance of genetic counselling allows a full discussion of all options in a situation of increased genetic risk and a free informed choice by parents.
Ultrasound screening for nuchal-translucency thickness can detect about 80% of trisomies. Unlike invasive procedures, it is socially acceptable almost everywhere. Effectiveness should increase by enhancing education and training and the systematic referral for fetal anomalies screening to accredited laboratories. Women identified by ultrasound as at risk are offered invasive procedures. Even if the advance of the capacities of ultrasound screening raises psychological issues for these pregnant women because they have to make an active and quick decision about whether to continue with their pregnancy, it is reported that ultrasound screening remains the preferred prenatal screening strategy for most women. 161 Screening on fetal cells obtained by CVS has a higher rate of false-positive results (1 -1.5%) as compared with amniocentesis (0.5%). Each procedure has less than 1 in 10 000 false-negative results. The sampling of fetal cells obtained by amniocentesis or CVS in order to make lists of disorders for which PND should be available or offered is rejected.
Finally, discussing preimplantation genetic diagnosis, it has been reported that in Belgium, 1/3 of clients requested it because of fertility problems, 1/3 because of repeated miscarriages or terminations of pregnancy after PND, and 1/3 on religious or ethical grounds. PGS will always have false-negative results, because 1/3 to 1/5 of embryos are mosaics. The experience with preimplantation genetic diagnosis is as yet small and much remains to be done to clarify success rates, diagnostic accuracy risks and longterm effects on the offspring.
Genetic screening programmes after birth
Discussions on genetic screening after birth have focused on disorders for which screening programs are debated. The inclusion of screening for conditions such as CF and DMD are currently being discussed throughout the countries. Although the original intent of neonatal screening is to identify genetic conditions in order to initiate early treatment and to prevent complications, the identification of new genes and technologies is extending the limits of what can be identified at the time of birth, oftentimes in the absence of treatment. This trend raises novel issues such as the systematic neonatal screening by using a test that can be performed on the blood spots routinely collected in screening for phenylketonuria and hypothyroidism, the methods and number of mutations to be tested, quality control, as well as the methods for presenting information.
In the UK, neonatal screening has been proposed for CF, on the basis of early intervention in both nutrition and infection. It has been reported that by 2 months and half, 40% of infants have lower bronchial infections. At the time of diagnosis, infants with CF are two standard deviations below the mean in weight, although they catch up around the age of 2 years. However, there is no evidence of any long-term effect of this nutritional compromise. Now 20% of newborns are screened and the programme is costeffective in terms of reduced mortality, even though on average screened infants are only diagnosed about 1 month earlier than unscreened infants.
Neonatal screening for DMD has been also recommended. In the United Kingdom, the Welsh research evaluation of newborn screening for DMD indicates that the great majority of identified families are in favor of screening and there has been no evidence of any long-term disruption in either the mother/baby relationship or family stability. Of 129 000 families who received information, 92% requested to have their child tested. Their reasons were right to know, planning for the future, and time to prepare emotionally. The parents of only two of the 22 children with DMD had post-decision regret. Concerning subsequent pregnancies, 74% of families had a prenatal diagnosis. There was no evidence of parental rejection of their living children identified as having DMD. In other respect, families changed their reproductive patterning after the neonatal diagnosis; there was a delay in family building reflected in the birth interval between index and second birth. These data confirm what Parsons et al 162 observed in 1996, namely genetic screening programmes for DMD should only be introduced if there is a rigorous protocol in place for handling positive cases and provision of ongoing support for identified families.
Genetic screening for fragile-X appears premature. Its prevalence is unknown, estimated at 1 in 2000 to 1 in 6000. There is an overlap between the 'normal' number of CGG repeats and the premutation number of repeats, further complicated by the possibly stabilising effect of varying numbers of AGG repeats within the CGG repeats. Furthermore, the number of repeats that may be unstable in families with fragile-X may be stable in the general population, suggesting that something else than the number of repeats is affecting these particular families. Fragile-X is underdiagnosed, resulting in lack of prevention of new cases. Ideally, the diagnosis should be made when the parents first notice 'something wrong', usually at about 1 year. This would relieve the parents of uncertainty and guilt. Finally, it has been suggested to screen pregnant women and women seeking preconceptional counselling, but only if questions about the overlap between normal and premutation can be answered.
Genetic screening for familial hypercholesterolemia seems also arguable. This type of screening is complicated by divergences between genotype and phenotype. Some individuals with familial hypercholesterolemia mutations do not have high cholesterol. Further, individuals with familial hypercholesterolemia mutations and high cholesterol develop heart disease at differing ages and with differing severity. Biochemical screening for cholesterol may be preferable to genetic screening. Similar genotypephenotype divergences have been observed for hemochromatosis screening. The place of the DNA test in the diagnosis and management of the disorder is not yet clear.
Are antenatal clinics the right place for carrier screening? Antenatal screening provides an effective way of identifying carriers and incorporating prenatal testing in this process. Carrier screening at antenatal clinics is easy to organize: the risk of being a carrier is of current interest and the partner already exists. On the other hand, couples have less options than before the pregnancy, time for decisionmaking is limited, and because of the pregnancy, carrier screening may cause extra anxiety. Couples may also be too stressed to make truly informed decisions. In other respects, the partner may not be available. In Finland, two pilot programmes have been set up for aspartylglycosaminuria screening. These programmes have been well received with a high rate of participation. The reasons given were (1) the health of the baby (93%) and (2) the participation in all tests offered (86%).
Of all the types of genetic screening, preconceptional carrier screening is the preferred way to go. However, the organization of adequate facilities to meet the demand for screening is essential. In the UK, it has been reported that screening for hemoglobinopathies in primary care could be enhanced; especially a multidisciplinary approach and a diagnosis laboratory responsive to the needs of local practitioners are important and facilitators like nurses can be particularly successful in persuading single-handed practitioners practising in areas with a high prevalence of ethnic groups to increase their testing for carriers. Simultaneously, additional approaches are necessary: for example, a strategy within the maternity services for taking parental blood in early pregnancy, especially in areas with a high proportion of ethnic groups, since preconceptional carrier screening is unlikely to replace antenatal screening. It is also recommended to pay more attention to minority groups. Results of a survey conducted by the Genetic Interest Group show that only five of 27 British genetics clinics recorded patients' ethnicity. Practitioners were left to determine patients' ethnic origins.
The decision-making process It has been reported that attention should always be paid to the possible psychological consequences for people who have decided not to take part in a screening programme and who are confronted with the birth of a child suffering from a disorder that screening would have detected. It has been observed that if they did not take this possibility sufficiently into account when they decided not to participate in screening, they may experience feelings of guilt and remorse. Proper information appears to be the only way to prevent this happening. To do so, an ongoing educational effort for groups of professionals and for the general population is essential to safeguard 'free informed decision making' in a context of genetic screening and to stimulate better coping in families confronted with genetic disease.
For that, underdisclosure and overloaded information should be avoided. It has been argued that informed consent is not an event, but a process of communication between a health provider and a patient at all the stages of the screening process.
Conclusion
Are population genetic screening programmes needed? Genetic testing is now a well-established part of medical care, which may benefit a number of different groups of individuals. Given the rarity of serious genetic conditions, the development of genetic screening programs, even in the light of new genetic knowledge, will not lead to the testing of all individuals. Instead, the offer of a test to a large subgroup of them, with the aim of identifying those at higher risk so that more specific tests may be offered could be considered. The number of conditions for which this might be considered would be small. For the population as a whole, CF is the obvious example and for ethnic groups, thalassemia is another example. Where screening programs of this type exist and are well organized, the participation rate is generally high, indicating that they satisfy a genuine need.
Simultaneously, experiences with population screening (eg hemoglobin disorders) have demonstrated the necessity to build up an interconnected comprehensive infrastructure of services, to educate physicians and the population to be screened not only about the nature of the disorder itself but also about the limits of the tests that are available to avoid unnecessary harm. It is agreed upon that one of the main problems is how appropriately controllable is the evolution of standards of practice by the medical profession as new powerful diagnostic tests rapidly become available by the new genetics. Protocols for screening programmes should be developed on basis of research evidence and caution should be taken for conditions for which there is no treatment.
It is agreed upon that if genetic screening programmes would be offered on a population basis a number of complex problems has to be solved, that is, who should be offered testing and in what setting? How should the lack of public understanding of genetics be dealt with? How should the training of health-care providers be improved ? How can individual autonomy be safeguarded? What kind of procedures should be taken to ensure the quality of genetic counselling?
Consensus has been reached that informed choice is the basis of every genetic screening programme. Because the majority of the population is as yet relatively uninformed, counselling is necessary to safeguard individual autonomy and choices. Health professionals' awareness and knowledge of genetics have to be improved. Collaboration with patients organizations is also needed to ensure that information surrounding the offer of a screening test reflects the perceived impact of the condition from the perspective of those affected, and provides information that those living with the condition would have found helpful had it been available prior to the offer of the test.
Danish National Board of Health, Guidelines and recommendations for indications for prenatal diagnosis, 1994 Danish Council of Ethics, Priority-setting in the Health Services, 1997: Genetic screening is mainly regulated through the legal regulations that in general applies to the Danish health care system.
Finland In 1997, the Ministry of Social Affairs and Health set up a Working Party to evaluate genetic screening programmes and the ethical and social issues involved with it. The Working Party gave its report in 1998: the main conclusion was that genetic screening programmes should always be approved by an official health care authority; the details of this should be legislated. There should be a national board of experts who should follow the research and practices concerning genetic screening.
There is no specific regulations of genetic testing in laboratories. The Ministry of Social Affairs and Health supervises genetic testing as part of supervision and quality control of both the public sector and the private laboratories. Recommendations on quality control have been published and updated several times by the Society for Medical Genetics. Laws No. 94-654 of 29 July 1994 on the donation and use of elements and products of the human body, medically assisted procreation and prenatal diagnosis: Prenatal diagnosis is defined as including medical techniques aimed at detecting in utero a particularly severe disorder but not necessarily incurable. It must be preceded by a medical genetic counselling consultation. The cytogenetic and biological analyses must be carried out in authorized establishments. Preimplantation diagnosis is only allowed in certain circumstances: a physician working in a pluridisciplinary prenatal diagnosis center must attest that a couple runs a high risk of having a child suffering from a particularly severe genetic disease that is incurable at the time of diagnosis; the genetic anomaly must have been identified in one of the parents; both members of the couple must give written consent to the test. The purpose of the test is limited to finding the affection, and looking for ways to prevent and treat it. National Ethical Consultative Committee for the Life and Health Sciences in France, Genetics and Medicine: From Prediction to Prevention, Paris, 1995: Genetic screening is the subject of this report, which in the absence of a specific law, declares the ethical principles that must be respected, with respect to all the activities involved in genetic screening. Its recommendations cover the following topics and ethical principles: respect of the autonomy of the subject, respect of medical confidentiality; respect of privacy in computerizing personal data; the use of biological samples; the prohibition of using results of genetic tests for purposes other than medical or scientific; procedures of accreditation of the materials involved in genetic testing; prior evaluation of the impact of the tests; information and formation of all medical personnel in genetics; the need to guarantee correct public information; prohibition of all uses that would contribute to stigmatization or unfair discrimination in the social and economic spheres. National Advisory Committee on Bioethics and National College of Gynaecologists and Obstetricians Guidelines, 1997: The topics covered by these guidelines are prenatal diagnosis, preimplantation diagnosis and predictive testing for late-onset diseases. The German Bundestag, Chancen und Risken der Gentechnologie Enquete-Commission, 1987: Prenatal diagnosis and newborn screening programmes were accepted. The document recommended the creation of a number of new offences in the German Criminal Code including the creation of a new offence of manipulating the germ line of a human being, and recommended a new criminal offence where an employer discriminates against an employee on the basis of the results of his genetic test. The report also contained detailed recommendations on the consent and counselling requirements which must be fulfilled before any genetic screening can be carried out. In most instances, the report did not recommend that legislation be enacted but rather that these matters be supervised by authoritative professional bodies. 112 The Embryo Protection Law of 1990: This law regulates medical actions around in vitro reproduction. It forbids by penalty to manipulate the embryos, to start more than three embryos, they are for implantation only. IVF is restricted to cases of infertility. Bundesministerium für Forschung und Technologie, Die Erforschung des menschlichen Genoms. Ethische und soziale Aspekte, 1990: The Federal Ministry of Research and Technology established a working group in order to evaluate the Ethical and Social Aspects of the Human Genome Analysis. Population screening and its problems was evaluated, as well as the screening with versus without medical indication and the necessity of informed consent vs informed refusal. 165 Berufsverband Medizinische Genetik, Stellungnahme zu einem möblichen Heterozygoten -Screening bei Cystischer fibrose, Medizinische Genetik, 1990: The German Medical Genetics Association published a Statement about Screening of Heterozygotes pointing to the danger of discrimination of carriers within an uneducated society. 165 The German Society of Human Genetics, 115 Statement on heterozygote screening, 1991: The German Society states that for population screening, the public must be fully and competently educated about the project and that there be guarantees that participation of the examinees is voluntary, that the examinees are able to comprehend the significance of their decision, that the individuals responsible for counselling and examination are qualified to do so, and that possible risks be evaluated beforehand. Therefore, the German Society rejects this type of population screening at present since the basic preconditions are not met. This applies to education of the public, the guarantee that the required counselling is qualified, and the carrying out of scientific projects on which future decisions can be based. Attempts are being made by some institutions today to review and discuss the technical possibilities of PGD, the question of its necessity, and the ethical, social and legal problems, in particular the necessary changes of the Embryo Protection Law and the professional guidelines for IVF. In addition, the reformed Abortion Law of 1995 still bans abortion but allows exceptions under certain conditions. The jurisdiction in the German constitution protects the diseased or disabled. Therefore a future disorder or disability of the foetus can not be used as sole reason for abortion. These principles cause difficulties in discussions pro PGD.
Greece In 1977, Greek legislation changed the abortion law to allow termination of the pregnancy up to the 24th week for medical reasons. There is no legislation concerning practice in genetics. Currently, a five-member Bioethics Committee, reporting directly to the Prime Minister is preparing guidelines regarding the ethical and social issues of genetic testing. Since 1981, the Hellenic Association of Medical Genetics has been trying to get approval from the government concerning a national genetics programme that would include all the existing units and establish new units of genetics all over the country under specific structure and organization. Quality control systems are not existent and the Hellenic Association of Medical Genetics has not been involved up until today in the organisation of such a system. 166 Iceland Iceland has no law that specifically deals with human genetics. There is a law (no. 18/1996) on genetically engineered organisms. The law on patients' rights (no. 74/1997) has some relevance here, as do laws on health-care service (97/1990 ), on personal privacy and data protection (121/1989) , and some other laws (eg 53/1988, 37/1993, 50/1996 Testing, 1998 : In May 1998, the Italian Government has approved the National Guidelines for Genetic Testing prepared by a Task Force. The general objectives are: (1) ensuring the safety and effectiveness of both existing and newly introduced genetic tests; (2) defining the criteria for quality assurance of laboratories performing genetic tests; (3) ensuring both adequate counselling and the free decision of individuals and families; this will include a particular attention to problems concerning ethics and privacy. Some topics deserving a specific concern have been identified, namely: genetic testing for prenatal diagnosis, genetic testing for susceptibility to cancer, and genetic testing for rare diseases. 167 Decreti presidenziali, 9 luglio 1999 (Gazzetta Ufficiale), Accertamenti per la diagnosi delle malformazioni (Art. Genetic testing for diagnostic purposes is permitted without restrictions, but the law requires that comprehensive genetic counselling be given before, during and after genetic tests performed on healthy persons for presymptomatic, predictive or carrier purposes. Presymptomatic, predictive and carrier testing is limited to individuals above the age of 16 years. When the information refers to a diagnostic test, genetic results may be communicated, without restrictions, between medical institutions authorized to apply medical biotechnology. However, the exchange of genetic information about presymptomatic, predictive or carrier tests is restricted. The Act states that it is prohibited to ask whether a presymptomatic, predictive or carrier test has been performed. Gene therapy is only allowed as somatic cell therapy and individuals below the age of 16 years need the consent of their parents or guardians. Spain There is no specific legislation to ensure the appropriateness of genetic procedures and the confidentiality of personal data. Consent to undergo to any medical tests is granted through General Health Law of 25 April 1986; article 10.6 states the right of a patient to choose freely between options given by the physician in charge of his case. Protection of data related to health may be reached through general rules concerning personal data protection, as well as through provisions which recognise the duty of confidentiality in the health field. The Organic Law regulating the automated processing and protection of personal data of 13 December 1999 provides special measures of protection for personal health data. Among other fundamental rights, the general legal principle of non discrimination is stated by the Spanish Constitution of 1978, which forbids any kind of discrimination on grounds of any personal condition. 170 Quality assessment schemes for genetic services have been addressed in specific areas. In 1996, standard criteria for quality control of cytogenetic and prenatal diagnosis laboratories were issued, and currently there are plans to develop quality standards for clinical and molecular genetic services. The Swedish Society for Medical Genetics has brought forward a quality assessment document for clinical genetic units including guidelines for cytogenetic and molecular routines as well as for genetic counselling. This document has been adopted by all the university clinical genetic departments as a minimum standard for quality. 171 The Ministry of Health and Social Affairs, Guidelines on the use of prenatal diagnosis and preimplantation diagnosis, 1995: These guidelines regulate prenatal diagnoses and include prenatal diagnosis by genetic tests. All pregnant women must be informed about prenatal diagnosis. Screening is in principle to be avoided in connection with prenatal diagnosis. Preimplantation diagnosis may only be used for the diagnosis of serious, progressive, hereditary diseases, which lead to premature death and for which there is no cure or treatment. National Board of Health and Social Welfare, Genetics in Health Care: Guidelines, 1999 The Agreement between the Swedish government and the Association of insurance companies, 1999: According to this agreement, the use of information about an individual that has been obtained by studying his genetic characteristics other than for medical purposes is prohibited. This agreement is valid to the year 2002.
Switzerland
The Swiss Federal Constitution, 1992: The Constitution provides laws on human genetic practice and medicalassisted procreation. Article 119 (introduced in 1992 as article 24 novies, old numbering) paragraph 2 states that the genetic make-up of an individual may be investigated, registered or divulged only with his consent or on the basis of a legal prescription. Article 24 novies forbids preimplantation diagnosis in either clinical or research settings. The Swiss Academy of Medical Sciences, Medical -ethical Guidelines for Genetic Investigations in Humans, Approved by the Senate of the Swiss Academy of Medical Sciences on 3 June 1993: Although there are no official national standards for genetic counselling, the medical -ethical guidelines define the content of genetic counselling in connection with genetic investigation for all physicians. 172 The medical -ethical guidelines also define the spectrum of activities belonging to genetic services in general. Quality control standards exist for laboratory investigations.
The Swiss Academy of Medical Sciences guidelines are not legally binding, unless cantonal legislation gives them binding force.
Bill regarding Genetic Investigations in Humans, September 1998: This bill has not yet been debated in Parliament. Section 2 allows genetic investigations for medical purposes. Article 10 describes conditions for genetic screening.
The Netherlands
The Population Screening Act, 1992 Act, (1996 The Convention sets out to preserve human dignity, rights and freedoms, through a series of principles and prohibitions. It does not refer explicitly to genetic screening, at most according to Article 5, a genetic test 'may only be carried out after the person concerned has given free and informed consent to it'; according to Article 12, 'tests which are predictive of genetic diseases or which serve either to identify the subject as a carrier of a gene responsible for a disease or to detect a genetic predisposition or susceptibility to a disease may be performed only for health purposes or for scientific research linked to health purposes, and subject to appropriate genetic counselling'. The restriction of genetic diagnostics to health or scientific purposes is reinforced by Article 11 that states that 'any form of discrimination against a person on grounds of his or her genetic heritage is prohibited'. However, the Convention does not say whether individuals who have had a genetic test for health or scientific purposes will be required to disclose the results of that test to an insurance company or an employer.
The Convention has endorsed the Council of Europe recommendations on genetic screening.
Council of Europe, Recommendation 1512 on the protection of the human genome, 2001
Australia Human genetic Society of Australasia, Newborn Screening, 1999: The HGSA proposed general recommendations for newborn screening: Newborn screening is recommended provided that: (i) there is benefit for the individual from early diagnosis. (ii) The benefit is reasonably balanced against financial and other costs. (iii) There is a reliable test suitable for newborn screening. (iv) There is a satisfactory system in operation to deal with diagnostic testing, counselling, treatment and follow-up of patients identifies by the test. Human Genetic Society of Australasia, Guidelines for the Practice of Genetic Counselling, 1999: This guidelines concerns the general practice of genetic counselling. However, the following citation refers to screening tests: 'Screening tests are non-diagnostic, population-based tests providing the client with a personalised risk. When performed prenatally, screening tests may identify fetal abnormalities or reveal an increased risk of fetal abnormalities. When performed post-natally, the aim of genetic screening is to identify individuals at increased risk of developing symptoms of a disorder in the future, with a view to offering intervention eg, newborn screening. The nature of a screening test should be clearly distinguished from a diagnostic test to the client. Appropriate written and/or verbal information should be provided prior to testing. Support and counselling should be made available to persons receiving a high-risk result so that future options are understood.' The Association recommends that all carrier testing must be voluntary, and informed consent from screened individuals is required. Confidentiality of results is to be maintained. Results of testing should not be disclosed to third parties without the explicit informed consent of the screened individual. Patients should be informed as to potential uses for the genetic information by third parties, and whether other ways of obtaining the information are available when appropriate. Carrier testing should be available uniformly among the at-risk population being screened. One legitimate exception to this principle is the limitation of carrier testing to individuals of childbearing age. In pursuit of uniform access, physicians should not limit testing only to patients specifically requesting testing. If testing is offered to some patients, it should be offered to all patients within the same risk category. The direction of future genetic screening tests should be determined by well thought out and well-coordinated social policy. Third parties, including insurance companies or employers, should not be permitted to discriminate against carriers of genetic disorders through policies that have the ultimate effect of influencing decisions about testing and reproduction. The ACMG Clinical Practice Committee, Principles of screening, 1997: The American College emphasizes the following points: * A screening programme should have a clearly defined purpose, whether the purpose is research or medical care * A screening programme is more than a laboratory test.
United States of America
Therefore, follow-up evaluation and counselling by genetic professionals must be guaranteed. * A screening programme should be reviewed by the appropriate board and be evaluated periodically to determine if it is meeting its goals. The ACMG, Policy Statement: Fragile X SyndromeDiagnostic and Carrier Testing, 1997 The ACMG, Standards and Guidelines for Clinical Genetics Laboratories, Second Edition, 1999: These voluntary standards are an educational resource to assist medical geneticists in providing accurate and reliable diagnostic genetic laboratory testing consistent with currently available technology and procedures in the areas of clinical cytogenetics, biochemical genetics and molecular diagnostics. These standards establish minimal criteria for clinical genetics laboratories. The Standards should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. The accuracy and dependability of all procedures should be documented in each laboratory. This should include in-house validation and/or references to appropriate published literature. Specialized testing, not available to all laboratories, requires appropriate and sufficient documentation of effectiveness to justify its use. In determining the propriety of any specific procedure or test, the medical geneticist should apply his/her own professional judgment to the specific circumstances presented by the individual patient or specimen. Medical geneticists are encouraged to document the reasons for the use of a particular procedure or test, whether or not it is in conformance with these Standards. These Standards will be reviewed and updated periodically to assure their timeliness in this rapidly developing field. The ACMG, Laboratory Standards and Guidelines for Population-based Cystic Fibrosis Carrier Screening, 2001: The Committee recommends that CF carrier screening be offered to non-Jewish Caucasians and Ashkenazi Jews, and made available to other ethnic and racial groups who will be informed of their detectability through educational brochures, the informed consent process, and/or other efficient methods. For example, Asian Americans and Native Americans without significant Caucasian admixture should be informed of the rarity of the disease and the very low yield of the test in their respective populations. Testing should be made available to African Americans, recognizing that only about 50% of at-risk couples will be detected. An educational brochure and a consent form which recites this information as well as a sign-off for those choosing not to be tested after reading these materials is being prepared by the Working Group on Patient Education and Informed Consent. The AAP has adopted these recommendations:
(1) Established newborn screening tests should be reviewed and evaluated periodically to permit modification of the programme or elimination of ineffective components. The introduction of new newborn screening tests should be conducted through carefully monitored research protocols. (2) Genetic tests, like most diagnostic or therapeutic endeavors for children, require a process of informed parental consent and the older child's assent. Newborn screening programmes are encouraged to evaluate protocols in which informed consent from parents is obtained. The frequency of informed refusals should be monitored. Research to improve the efficiency and effectiveness of informed consent for newborn screening is warranted. (3) The AAP does not support the broad use of carrier testing or screening in children or adolescents. Additional research needs to be conducted on carrier screening in children and adolescents. The risks and benefits of carrier screening in the pediatric population should be evaluated in carefully monitored clinical trials before it is offered on a broad scale. Carrier screening for pregnant adolescents or for some adolescents considering pregnancy may be appropriate. (4) Genetic testing for adult-onset conditions generally should be deferred until adulthood or until an adolescent interested in testing has developed mature decision-making capacities. The AAP believes that genetic testing of children and adolescents to predict late-onset disorders is inappropriate when the genetic information has not been shown to reduce morbidity and mortality through interventions initiated in childhood. (5) Because genetic screening and testing may not be well understood, pediatricians need to provide parents the necessary information and counseling about the limits of genetic knowledge and treatment capabilities, the potential harm that may be done by gaining certain genetic information, including the possibilities for psychological harm, stigmatization, and discrimination, and medical conditions and disability and potential treatments and services for children with genetic conditions. Pediatricians can be assisted in managing many of the complex issues involved in genetic testing by collaboration with geneticists, genetic counsellors, and prenatal care providers. (6) The AAP supports the expansion of educational opportunities in human genetics for medical students, residents, and practicing physicians and the expansion of training programmes for genetic professionals.
